Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Arcturus TherapeuticsTheravance BiopharmaIndiviorConstellation PharmaceuticalsNorthwest Biotherapeutics
SymbolNASDAQ:ARCTNASDAQ:TBPHOTCMKTS:INVVYNASDAQ:CNSTOTCMKTS:NWBO
Price Information
Current Price$38.24$22.46$9.91$22.12$1.39
52 Week RangeHoldBuyBuyBuyN/A
MarketRank™
Overall Score1.61.60.81.20.5
Analysis Score3.13.50.03.40.0
Community Score2.62.41.92.42.7
Dividend Score0.00.00.00.00.0
Ownership Score1.71.70.00.00.0
Earnings & Valuation Score0.60.61.90.00.0
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyN/A
Consensus Price Target$70.67$33.29N/A$45.29N/A
% Upside from Price Target84.80% upside48.20% upsideN/A104.73% upsideN/A
Trade Information
Market Cap$1.00 billion$1.46 billion$1.46 billion$1.06 billion$1.17 billion
Beta3.010.940.32.80.93
Average Volume1,169,061349,9129,198459,0822,221,656
Sales & Book Value
Annual Revenue$20.79 million$73.41 million$785 millionN/A$2.41 million
Price / Sales48.3419.951.85N/A487.16
CashflowN/AN/A$1.98 per shareN/AN/A
Price / CashN/AN/A5.01N/AN/A
Book Value$1.70 per share($3.94) per share$1.43 per share$8.23 per share($0.07) per share
Price / Book22.49-5.706.93N/A-19.86
Profitability
Net Income$-25,990,000.00$-236,460,000.00$134 million$-85,550,000.00$-20,300,000.00
EPS($2.15)($4.25)$1.15($3.04)N/A
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/A16.80N/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-506.70%-345.16%-31.93%N/A-2,658.66%
Return on Equity (ROE)-52.32%N/A-4.15%-28.88%N/A
Return on Assets (ROA)-33.21%-51.60%-0.26%-24.98%-47.19%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.06%N/A2.89%0.05%N/A
Current Ratio11.21%4.32%1.82%15.81%0.09%
Quick Ratio11.21%4.32%1.69%15.81%0.09%
Ownership Information
Institutional Ownership Percentage74.33%80.41%N/AN/A0.02%
Insider Ownership Percentage12.60%5.90%N/A10.60%21.30%
Miscellaneous
Employees11835979615417
Shares Outstanding26.28 million65.22 million146.92 million47.86 million844.65 million
Next Earnings Date5/6/2021 (Estimated)5/4/2021 (Confirmed)5/13/2021 (Estimated)5/5/2021 (Estimated)6/23/2021 (Estimated)
OptionableOptionableOptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Northwest Biotherapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Northwest Biotherapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - April 20 at 1:06 PM
Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Above 50-Day Moving Average of $1.46Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Above 50-Day Moving Average of $1.46
americanbankingnews.com - April 20 at 2:36 AM
Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Above Fifty Day Moving Average of $1.46Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Price Crosses Above Fifty Day Moving Average of $1.46
americanbankingnews.com - April 20 at 2:36 AM
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Northwest Biotherapeutics, Inc. for Potential Breach of Fiduciary Duty ClaimsINVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Northwest Biotherapeutics, Inc. for Potential Breach of Fiduciary Duty Claims
finance.yahoo.com - April 17 at 5:59 PM
Comparing Northwest Biotherapeutics (OTCMKTS:NWBO) & Nabriva Therapeutics (NASDAQ:NBRV)Comparing Northwest Biotherapeutics (OTCMKTS:NWBO) & Nabriva Therapeutics (NASDAQ:NBRV)
americanbankingnews.com - April 12 at 2:10 PM
Northwest Biotherapeutics (OTCMKTS:NWBO) Shares Pass Below Two Hundred Day Moving Average of $1.37Northwest Biotherapeutics (OTCMKTS:NWBO) Shares Pass Below Two Hundred Day Moving Average of $1.37
americanbankingnews.com - April 3 at 1:36 AM
Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK FacilityNorthwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility
finance.yahoo.com - March 16 at 12:10 PM
Northwest Bio: The Endgame Is ApproachingNorthwest Bio: The Endgame Is Approaching
seekingalpha.com - March 11 at 3:32 PM
Northwest Biotherapeutics: 3Q Earnings SnapshotNorthwest Biotherapeutics: 3Q Earnings Snapshot
chron.com - January 15 at 11:39 PM
Northwest Biotherapeutics: Blinded By The Dazzle Of The UnblindingNorthwest Biotherapeutics: Blinded By The Dazzle Of The Unblinding
seekingalpha.com - December 20 at 12:39 PM
3 Penny Stocks To Buy On Robinhood Under $3 Right Now3 Penny Stocks To Buy On Robinhood Under $3 Right Now
marketwatch.com - December 19 at 5:51 PM
Cel-Sci Long Awaited Head And Neck Trial Phase III: Data LockedCel-Sci Long Awaited Head And Neck Trial Phase III: Data Locked
seekingalpha.com - December 14 at 4:45 PM
DEDUCED RECKONING: Northwest Bio awaits trial resultsDEDUCED RECKONING: Northwest Bio awaits trial results
heraldtribune.com - November 12 at 2:49 PM
Is Northwest Biotheraputics a Buy Ahead of Its Brain Tumor Vaccine Clinical Data Release?Is Northwest Biotheraputics a Buy Ahead of Its Brain Tumor Vaccine Clinical Data Release?
finance.yahoo.com - October 28 at 8:01 AM
Northwest Biotherapeutics Announces Data Lock of Phase III TrialNorthwest Biotherapeutics Announces Data Lock of Phase III Trial
prnewswire.com - October 5 at 12:26 PM
Northwest Biotherapeutics locks Phase 3 data from brain tumor studyNorthwest Biotherapeutics locks Phase 3 data from brain tumor study
seekingalpha.com - October 5 at 12:26 PM
Northwest Biotherapeutics locks Phase III trial dataNorthwest Biotherapeutics locks Phase III trial data
seekingalpha.com - October 5 at 12:26 PM
Cell Therapy Concern Announces Breakthrough, Shares SoarCell Therapy Concern Announces Breakthrough, Shares Soar
baystreet.ca - September 2 at 1:43 AM
Northwest Biotherapeutics high on Flaskworks acquisitionNorthwest Biotherapeutics high on Flaskworks acquisition
seekingalpha.com - September 1 at 3:43 PM
Northwest Biotherapeutics Acquires FlaskworksNorthwest Biotherapeutics Acquires Flaskworks
finance.yahoo.com - September 1 at 10:42 AM
NW Bio Accelerating Sawston Plant Phase I BuildoutNW Bio Accelerating Sawston Plant Phase I Buildout
finance.yahoo.com - August 27 at 10:40 AM
Northwest Biotherapeutics secures loan financing of $5MNorthwest Biotherapeutics secures loan financing of $5M
seekingalpha.com - August 21 at 3:03 PM
Northwest Biotherapeutics Announces $5 Million FinancingNorthwest Biotherapeutics Announces $5 Million Financing
finance.yahoo.com - August 21 at 3:03 PM
Northwest Biotherapeutics, Inc. (NWBO)Northwest Biotherapeutics, Inc. (NWBO)
uk.finance.yahoo.com - August 12 at 10:54 PM
Northwest Biotherapeutics reports Q2 resultsNorthwest Biotherapeutics reports Q2 results
seekingalpha.com - August 11 at 3:39 PM
DateCompanyBrokerageAction
3/8/2021Arcturus TherapeuticsB. RileyLower Price Target
3/2/2021Arcturus TherapeuticsRoth CapitalLower Price Target
1/7/2021Arcturus TherapeuticsWells Fargo & CompanyInitiated Coverage
12/29/2020Arcturus TherapeuticsHC WainwrightDowngrade
12/29/2020Arcturus TherapeuticsRobert W. BairdDowngrade
12/29/2020Arcturus TherapeuticsBarclaysDowngrade
12/29/2020Arcturus TherapeuticsRaymond JamesDowngrade
12/14/2020Arcturus TherapeuticsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
12/14/2020Arcturus TherapeuticsSmith Barney CitigroupBoost Price Target
8/25/2020Arcturus TherapeuticsPiper SandlerInitiated Coverage
8/11/2020Arcturus TherapeuticsBrookline Capital ManagementReiterated Rating
4/1/2021Theravance BiopharmaSVB LeerinkLower Price Target
3/8/2021Theravance BiopharmaMorgan StanleyLower Price Target
11/23/2020Theravance BiopharmaEvercore ISIReiterated Rating
7/7/2020Theravance BiopharmaJPMorgan Chase & Co.Initiated Coverage
5/13/2020Theravance BiopharmaCowenInitiated Coverage
11/6/2019Theravance BiopharmaPiper Jaffray CompaniesLower Price Target
8/16/2019Theravance BiopharmaCantor FitzgeraldSet Price Target
7/27/2020IndiviorJefferies Financial GroupUpgrade
7/27/2020IndiviorStifel NicolausUpgrade
4/7/2021Constellation PharmaceuticalsRoyal Bank of CanadaReiterated Rating
1/25/2021Constellation PharmaceuticalsBMO Capital MarketsUpgrade
9/24/2020Constellation PharmaceuticalsOppenheimerReiterated Rating
6/24/2020Constellation PharmaceuticalsJMP SecuritiesInitiated Coverage
2/13/2020Constellation PharmaceuticalsSunTrust BanksInitiated Coverage
5/29/2018Northwest BiotherapeuticsS&P Equity ResearchLower Price Target
(Data available from 4/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.